PRIDE-HDon behalf of the HSG PRIDE-
HD InvestigatorsHSG Presentation of Trial
ResultsNovember 3, 2016
HART
on behalf of the HSG HART Investigators
HDCRS Presentation of Trial Results
October 16, 2010
Pridopidine represents a novel therapeutic class of agents: dopamine stabilizers
High
Low
Normal
psychomotor activityPridopidine
High
Low
Normal
psychomotor activityStandard antipsychotic
Phase II Trial in Huntington Disease
• Randomized, double-blind, placebo controlled trial
• n = 58• Pridopidine 50 mg/d (n = 28)• Followed for 28 days
*Component of Modified Motor Score
Components of the Total Motor Scale of the UHDRS, with
Modified Motor Score Highlighted
Ocular Pursuit
Saccade Initiation
Saccade Velocity
Dysarthria*Tongue Protrusion*Finger Taps*Pronate/Supinate Hands*Luria (Fist-hand-palm test)*Rigidity – arms*Body bradykinesia*Maximal Dystonia
Maximal Chorea
Gait*Tandem Walking*Retropulsion Pull Test*
Clinical motor improvement by pridopidine – HART and MermaiHD studies results
5
• Phase III study with 437 patients in eight European countries
• Significant effects on TMS after 26 weeks; -3.0 points (p = 0.004)
• The primary endpoint (mMS) was not met
• Phase IIb study with 227 patients in the United States and Canada
• Significant effect on TMS after 12 weeks; -2.8 points (p = 0.039)
• Primary endpoint (mMS) was not met
HART studyMermaiHD study
Huntington Study Group HART Investigators. Mov Disord. 2013 Sep;28(10):1407-15. Yebenes JG, et al. Lancet Neurol. 2011 Dec;10(12):1049-57.
Disclaimer
–Data presented here is based on topline phase 2 analysis
–Further analysis is being undertaken
–Additional data will be presented at forthcoming meetings
–Teva plans to submit results for publication
6
Initial PRIDE-HD design: Evaluation of safety, tolerability and efficacy of higher doses (≥45mg bid) for symptomatic (motor) effects
– Global Ph2, dose-ranging study to build on HART and MermaiHD’s findings– Study Duration: 26 wks; adequate for evaluation of motor effects– 4 doses (45, 67.5, 90, 112.5) and placebo – x2.5 higher that HART and MermaiHD– Population: 400 patients no HD stage restrictions – subjects had minimal TMS ≥
25– 52 sites– Endpoints: focused on motor symptoms (TMS, mPPT)
7
8
PRIDE-HD Chronology of Events:
–26-week protocol finalization: May 2013–Type C meeting: July 2013–First subject first visit: Jan 2014–52-week amendment: October 2014–Enrolment Completion: June 2015–26-week readout: January 2016–52-week readout: August 2016–Press release: September 2016
Based on new insights into Pridopidine MoA
9
Pridopidine may have broader effect beyond symptomatic relief
Phase 2 protocol modified to explore long-term effect on
function and rate of progression (52wks) & safety and tolerability
Total Functional Capacity* is an established endpoint to assess function and disease progression in HD: pre-specified and collected at 26 and 52 weeks
* Shoulson et al. Neurology 1981
PRIDE-HD recruited all stages of HD
10
• Steepest rate of natural decline• Most sensitive to current clinical measures• HD-CAB and TRACK-HD assessments designed
specifically for this period and earlier
• Difficulty completing assessments• Floor and ceiling effects limit ability to track
change• Very significant brain tissue loss
yrs
3
5
5-8
>8
No significant effect on TMS in the Full Analysis Set (FAS) at week 26
11
• All groups showed improvement from baseline
• Large placebo effect was observed
• Similar effects seen at 52 wks
Total Functional Capacity (TFC)
Total Functional Capacity is the most widely accepted tool for assessing functional decline in HD
13
• A well established endpoint for trials aiming to slow clinical progression
• Range: 0-13• Floor and ceiling effects make this more
sensitive to change in early HD, than late HD
Source: Shoulson et al. Neurology 1981
Annual rates of decline in TFC are higher in earlier stages of disease
14 Source: K. Marder et al. Neurology 2000;54:452
HD1 (11-13) HD2 (7-10) HD3 (3-6) HD4 (1-2)
A ‘significant’ slowing of functional decline as measured by TFC is seen
15
45 mg bid 67.5 mg bid 90 mg bid 112.5 mg bidN 59 54 56 58Wk52 ∆ to placebo 1.16 0.36 0.71 0.27p value 0.0003 0.2704 0.0239 0.4144
Impr
ovem
ent
Adj. means ± SEM
Placebo 45 mg bid 67.5 mg bid 90 mg bid 112.5 mg bid
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
Chan
ge fr
om B
asel
ine
Week 52
45 mg bid 67.5 mg bid 90 mg bid 112.5 mg bidN 75 79 81 81Wk52 ∆ to placebo 0.87 0.11 0.19 0.24p value 0.0032 0.7042 0.5099 0.4061
Impr
ovem
ent
Adj. means ± SEM
Placebo 45 mg bid 67.5 mg bid 90 mg bid 112.5 mg bid
-1.6
-1.2
-0.8
-0.4
0
0.4
0.8
Chan
ge fr
om B
asel
ine
Week 52
Full Analysis Set - pre-specified Early Stage (HD1 and HD2) - post-hocTFC annual decline in placebo as expected
The effect on TFC first observed at 26wks
16
17
Responder Analysis: significant difference in the proportion of subjects that showed no decline in TFC over 52wks between Pridopidine and placebo arms
Responder Analysis Questions Observed Data Analysis45mg bidN=37
PlaceboN=41
1. What proportion of early stage subjects had no deterioration on TFC (score ≥0) at 52 weeks?
30(81%) 20(49%)
Nominal P-value (Chi-Square) 0.0031. What proportion of early stage subjects
had an improvement of ≥1 points on TFC at 52 weeks?
10 (27%) 5 (12%)
Nominal P-value (Chi-Square) 0.099
Timed Up and Go Test (sec): Early HD at 52 wks
18
Summary: Pridopidine shows potential effect on functional decline as measured by TFC
• TFC - an accepted endpoint for functional decline in HD
• Effect on TFC was more pronounced in early HD, and also was observed in responder analysis
• The placebo arm declined as expected
• Effects were observed primarily with 45mg bid and 90mg bid, suggesting a non-linear dose response
• Improvement in ambulation may be contributing to TFC effect
19
Safety and Tolerability
PRIDE-HD: Summary of safety and tolerability
No new findings – Safety and tolerability profile fully compatible with Phase 3 developmentECG• QTcF analysis ongoing
Vital Signs• Dose dependent increase of heart rate• No effect on blood pressure
Labs• No clinically significant abnormalities observed
Psychiatric AEs: Summary & Conclusions
• Psychiatric events reported in all arms
• Irritability (most frequently observed psychiatric event) was more prevalent in placebo group (9%)
• Depression (relatively small number of events) reported in all arms
• Suicidality (relatively small number of events) reported in active arms • Columbia suicidality score change from “Negative” to “Positive” reported in all arms
including placebo
• Rates consistent with published literature
: Summary: Pridopidine shows effect on functional decline measured by TFC, an index of clinical progression
• First of 12 trials to show slowing of functional decline as measured by TFC - the gold standard scale for measuring HD clinial progressionEffect on TFC was significant at 52wks in the full analysis set and in early stage HD at
both 26 and 52wks
• Preclinical data generated in the last 3yrs support the effects on functional decline
• Large placebo response masked motor effects in the full analysis set
• Motor effects were observed in early HD subpopulations
• No new safety and tolerability issues
• PRIDE-HD supports further development23
Acknowledgements
–Patients and their families
–The clinical investigators and sites
–The PRIDE-HD Steering Committee: Karl Kieburtz, Bernhard Landwehrmeyer, Ralf Reilmann, Andy McGarry
–Teva clinical development team led by Spyros Papapetropoulos: Katie Blatt, Igor Grachev and Juha Savola
24
Investigators Slide 1 or 2
12 Countries, 52 sites:Australia
Andrew ChurchyardAnita GohClement LoyPeter Panegyres
AustriaKlaus SeppiRaphael Bonelli
CanadaBlair LeavittMark GuttmanTilak Mendis
DenmarkAnette Torvin MollerLena Hjermind
FranceAnne Catherine Bachoud-LeviChristophe VernyClemence SimoninFabienne CalvasJean-Philippe AzulayPierre Krystkowiak
GermanyCarsten SaftJosef PrillerMichael OrthRalf Reilmann
ItalyFerdinando SquitieriGiuseppe De MichelePaola SoliveriSandro Sorbi
Investigators Slide 2 or 2
Netherlands United StatesNasir Ahmad Aziz Andrew Feigin
Poland Christopher RossDaniel Zielonka Claudia TestaGrzegorz Witkowski David ShprecherJaroslaw Slawek Francis WalkerMonika Rudzinska Jody Corey-Bloom
Russia Karen AndersonAlexander Gustov Karen MarderSergey Illarioshkin Kevin BiglanZuleykha Abdullazarovna Zalyalova Pinky Agarwal
United Kingdom Susan PerlmanAndrea Nemeth Valarie SuskiAnne Rosser Victoria SegroDavid CraufurdHugh RickardsOliver QuarrellRoger BarkerSuresh Kumar Komati
Top Related